Prague Med. Rep. 2017, 118, 128-138
https://doi.org/10.14712/23362936.2017.14
5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line
References
1. 2007) 5-fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res. 67, 940–945.
< , Q., Robins, P., Lindahl, T., Barnes, D. E. (https://doi.org/10.1158/0008-5472.CAN-06-2960>
2. 2011) The use of real-time cell analyzer technology in drug discovery: Defining optimal cell culture conditions and assay reproducibility with different adherent cellular models. J. Biomol. Screen. 16, 575–587.
< , F. A., Tilmant, K., Gerets, H. H., Toussaint, G., Speeckaert, S., Hanon, E., Depelchin, O., Dhalluin, S. (https://doi.org/10.1177/1087057111402825>
3. 1993) Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil. Anticancer Res. 13, 789–793.
, T., Kralovanszky, J., Gyergyay, F., Kiss, E., Peters, G. J. (
4. 2004) Letter to the editor – 5-FU induced palmar-plantar erythrodyesthesia – a hospital pharmacy developed “antidot”. J. Oncol. Pharm. Pract. 10, 57.
< , J. (https://doi.org/10.1191/1078155204jp120xx>
5. 2002) Moving forward with capecitabine: a glimpse of the future. Oncologist 7, 29–35 (Suppl. 6).
, L., Martin, M., Twelves, C. (
6. 1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106, 761–771.
< , P., Petrussevska, R. T., Breitkreutz, D., Hornung, J., Markham, A., Fusenig, N. E. (https://doi.org/10.1083/jcb.106.3.761>
<PubMed>
7. 1997) Modulation of 5-fluorouracil in mice using uridine diphosphoglucose. Clin. Cancer Res. 3, 309–315.
, G., Kralovanszky, J., van der Wilt, C. L., Noordhuis, P., Colofiore, J. R., Martin, D. S., Franchi, F., Peters, G. J. (
8. 2008) Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin. Nucleosides Nucleotides Nucleic Acids 27, 733–739.
< , G., Noordhuis, P., van der Wilt, C. L., Peters, G. J. (https://doi.org/10.1080/15257770802145496>
9. 2009) NCCN Clinical Practice Guidelines in Oncology: colon cancer. J. Natl. Compr. Canc. Netw. 7, 778–831.
< , P. F., Arnoletti, J. P., Benson, A. B. 3rd, Chen, Y. J., Choti, M. A., Cooper, H. S., Covey, A., Dilawari, R. A., Early, D. S., Enzinger, P. C., Fakih, M. G., Fleshman, J. Jr., Fuchs, C., Grem, J. L., Kiel, K., Knol, J. A., Leong, L. A., Lin, E., Mulcahy, M. F., Rao, S., Ryan, D. P., Saltz, L., Shibata, D., Skibber, J. M., Sofocleous, C., Thomas, J., Venook, A. P., Willett, C. (https://doi.org/10.6004/jnccn.2009.0056>
10. 2012) Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br. J. Cancer 107, 1678–1683.
< , R. D., Heinemann, V., von Weikersthal, L. F., Laubender, R. P., Gencer, D., Burkholder, I., Hochhaus, A., Stintzing, S. (https://doi.org/10.1038/bjc.2012.434>
<PubMed>
11. 2006) The hand-foot syndrome – A frequent secondary manifestation in antineoplastic chemotherapy. Eur. J. Dermatol. 16, 494–499.
, M., Fischer, M., Marsch, W. C., Holzhausen, H. J., Kegel, T., Helmbold, P. (
12. 2011) Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Clin. Breast Cancer 11, 349–356.
< , R., Hennessy, B. T., Blum, J. L., O’Shaughnessy, J. (https://doi.org/10.1016/j.clbc.2011.06.005>
13. 1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol. 7, 425–432.
< , J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., Fryer, J. G. (https://doi.org/10.1200/JCO.1989.7.4.425>
14. 2003) 5-fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330–338.
< , D. B., Harkin, D. P., Johnston, P. G. (https://doi.org/10.1038/nrc1074>
15. 1980) An overview of thymidine. Cancer 45, 1117–1128.
< , D. S., Stolfi, R. L., Sawyer, R. C., Nayak, R., Spiegelman, S., Young, C. W., Woodcock, T. (https://doi.org/10.1002/1097-0142(19800315)45:5+<1117::AID-CNCR2820451316>3.0.CO;2-S>
16. 1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63.
< , T. (https://doi.org/10.1016/0022-1759(83)90303-4>
17. Netíková, I., Sedláčková, E., Konopásek, B., Petruželka, L. (2009) Therapy of palmar-plantar erythrodysesthesia after continual fluoropyrimidin administration with 10% uridin ointment (ASCO Meeting Abstract). J. Clin. Oncol. 27.
18. 1997) Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. U. S. A. 94, 1795–1799.
< , D. M., Watson, A. J., Potten, C. S., Jackman, A. L., Hickman, J. A. (https://doi.org/10.1073/pnas.94.5.1795>
<PubMed>
19. 1984) Effect of uridine on the metabolism of 5-fluorouracil in the CD8F 1 murine mammary carcinoma system. Pharm. Res. 1, 69–75.
< , R. C., Stolfi, R. L., Spiegelman, S., Martin, D. S. (https://doi.org/10.1023/A:1016351330832>
20. 2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann. Oncol. 23, 2479–2516.
< , H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., Nagtegaal, I. D., Beets-Tan, R. G., Arnold, D., Ciardiello, F., Hoff, P., Kerr, D., Kohne, C. H., Labianca, R., Price, T., Scheithauer, W., Sobrero, A., Tabernero, J., Aderka, D., Barroso, S., Bodoky, G., Douillard, J. Y., El Ghazaly, H., Gallardo, J., Garin, A., Glynne-Jones, R., Jordan, K., Meshcheryakov, A., Papamichail, D., Pfeiffer, P., Souglakos, I., Turhal, S., Cervantes, A. (https://doi.org/10.1093/annonc/mds236>
21. 1968) Comparative studies of fluorinated pyrimidines with various cell lines. Cancer Res. 28, 2529–2538.
, M., Heidelberger, C. (
22. 1992) Modulation of fluorouracil toxicity with uridine. Semin. Oncol. 19, 148–154.
, C. J., Peters, G. J., Pinedo, H. M. (
23. 2008) Systemic treatment of colorectal cancer. Gastroenterology 134, 1296–1310.
< , B. M., Mayer, R. J. (https://doi.org/10.1053/j.gastro.2008.02.098>
<PubMed>
24. 1994) New mechanism of action of the cancer chemotherapeutic agent 5-fluorouracil in human cells. J. Pharmacol. Exp. Ther. 269, 39–43.
, J. C., Tallarida, R. J., Sirover, M. A. (
25. 2008) Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin. Cancer Res. 14, 8–13.
< , J. L., Goldberg, R. M., McLeod, H. L. (https://doi.org/10.1158/1078-0432.CCR-07-1225>
26. 2010) Oncologic outcome after cessation or dose reduction of capecitabine in patients with colon cancer. J. Korean Soc. Coloproctol. 26, 287–292.
< , J. A., Kim, H. C., Son, H. S., Kim, H. R., Yun, H. R., Cho, Y. B., Yun, S. H., Lee, W. Y., Chun, H. K. (https://doi.org/10.3393/jksc.2010.26.4.287>
<PubMed>